Last reviewed · How we verify
Tj-14 (baicalin)
Tj-14 (generic name: baicalin) is a drug. It is currently in unknown development.
Tj-14 works by blocking the enzyme LSD1, which is involved in turning off genes by removing methyl groups from histones.
Baicalin is a small molecule compound that is the glucuronide of the polyphenolic compound baicalein. It is classified as a small molecule modality.
At a glance
| Generic name | baicalin |
|---|---|
| Target | Cyclin-dependent kinase 1, Lysine-specific histone demethylase 1A, Prolyl endopeptidase |
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of histones like the packaging materials for your genes. LSD1 is like a remover that takes the labels (methyl groups) off the packaging, making it harder for the genes to be turned on. By blocking LSD1, Tj-14 helps keep the labels on, making it easier for the genes to be turned on and potentially leading to changes in how the body works.
Approved indications
Common side effects
Key clinical trials
- Physiological Effects of Nutritional Support in Patients With Parkinson's Disease (NA)
- A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of LasoperinTM on Cognitive Function in Healthy Adults (NA)
- Effect of Mebo Dressing Versus Standard Care on Managing Donor and Recipient Sites of Split-thickness Skin Graft (PHASE1)
- MEBO Ointment and Hyaluronic Acid Gel in the Management of Pain After Free Gingival Graft Harvesting (PHASE1,PHASE2)
- Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tj-14 CI brief — competitive landscape report
- Tj-14 updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Tj-14
What is Tj-14?
How does Tj-14 work?
What is the generic name of Tj-14?
What development phase is Tj-14 in?
What does Tj-14 target?
Related
- Target: All drugs targeting Cyclin-dependent kinase 1, Lysine-specific histone demethylase 1A, Prolyl endopeptidase
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing